Oncology Drug Development Not Advanced By Non-Inferiority Trials – Pazdur
Executive Summary
Superiority trials should be favored over non-inferiority studies for oncology drug development, FDA Oncology Drug Products Division Director Richard Pazdur, MD, suggested
You may also be interested in...
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)
FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says
FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai